BPC-157 + TB-500 Synergy
The combination of BPC-157 (Body Protection Compound-15) and TB-500 (Thymosin Beta-4 / Ac-SDKP) represents a complementary peptide strategy for accelerated tissue regeneration, leveraging distinct but overlapping mechanisms of action for enhanced wound healing, angiogenesis, and tissue repair.
Overview
BPC-157 and TB-500 target different aspects of the tissue repair process. BPC-157 acts primarily through modulation of the nitric oxide (NO) system, angiogenic growth factor upregulation, and fibroblast activation, while TB-500 facilitates cell migration through actin sequestration, endothelial cell chemotaxis, and extracellular matrix remodeling. When used in combination, these peptides provide a more comprehensive regenerative stimulus than either agent alone.
| Peptide |
Primary Mechanism |
Speed of Action |
Tissue Focus |
| BPC-157 |
NO modulation, VEGF/FGF upregulation, gastroprotection |
Fast (days) |
GI tract, tendons, nerves |
| TB-500 |
Actin binding, angiogenesis, ECM remodeling |
Moderate (days to weeks) |
Muscle, skin, cardiac |
| Combination |
Complementary angiogenic + cytoprotective |
Rapid (days) |
Multi-tissue regenerative synergy |
🔬 Mechanisms of Synergy
Complementary Angiogenesis
BPC-157 and TB-500 both promote angiogenesis through distinct pathways:
- BPC-157 upregulates VEGF and FGF via NO-dependent mechanisms
- TB-500 directly stimulates endothelial cell migration and tube formation
- Combined effect: Enhanced capillary density and faster revascularization of injured tissue
Coordinated Cell Migration
- BPC-157 stimulates fibroblast and keratinocyte proliferation and migration
- TB-500 facilitates actin dynamics required for cellular motility
- Together: More efficient cellular infiltration into wound sites
Balanced Inflammatory Response
- Both peptides downregulate pro-inflammatory cytokines (TNF-α, IL-1β)
- Both upregulate anti-inflammatory mediators (IL-10, TGF-β)
- Result: Optimized inflammatory phase resolution without excessive suppression
Matrix Remodeling
- BPC-157 enhances collagen type I and III synthesis
- TB-500 modulates MMP activity for appropriate ECM turnover
- Combined: Improved scar quality and tensile strength
📊 Comparative Properties
| Property |
BPC-157 |
TB-500 (Ac-SDKP) |
| Molecular Weight |
1419.5 Da |
500.5 Da |
| Amino Acids |
15 |
4 (active fragment) |
| Half-life |
~15 min (plasma) |
~2–6 h |
| Solubility |
Hydrophilic (logP −2.8) |
Hydrophilic (logP −3.1) |
| Stability (Lyophilized) |
≥ 24 months at −20°C |
≥ 24 months at −20°C |
| Primary Mechanism |
NO modulation, VEGF/FGF |
Actin sequestration, cell migration |
| Research Dose |
200–500 μg daily |
2.5–5 mg 1–2×/week |
Synthesis Pathway Comparison
| Parameter |
BPC-157 |
TB-500 (Ac-SDKP) |
| SPPS Method |
Fmoc-SPPS, Rink amide resin |
Fmoc-SPPS, Rink amide resin |
| N-Terminal Modification |
Free amine |
Acetylated (Ac) |
| Amino Acids |
15 residues |
4 residues |
| Coupling Reagents |
HBTU/HOBt/DIPEA |
HBTU/HOBt/DIPEA |
| Cleavage |
TFA/TIPS/H₂O (95:2.5:2.5) |
TFA/TIPS/H₂O (95:2.5:2.5) |
| Crude Purity |
~70–85% |
~75–88% |
| Purification |
Preparative RP-HPLC (C18) |
Preparative RP-HPLC (C18) |
| Typical Yield |
15–25% |
20–35% |
| Salt Form |
Trifluoroacetate (TFA salt) |
Trifluoroacetate (TFA salt) |
🔬 AMP Peptide's 5,000 m² cGMP facility produces research-grade peptides via SPPS with HPLC purification and lyophilization.
Stability Compatibility Data
| Parameter |
BPC-157 |
TB-500 (Ac-SDKP) |
Combined Notes |
| Lyophilized Stability (−20°C) |
≥ 24 mo (> 95% purity) |
≥ 24 mo (> 95% purity) |
Store separately in sealed vials |
| Solution Stability (2–8°C) |
7 days |
7 days |
Compatible if mixed immediately before use |
| Solution Stability (25°C) |
24 h |
48 h |
Avoid prolonged co-incubation |
| Optimal pH Range |
5.5–6.5 |
5.5–6.5 |
Fully compatible range |
| Co-formulation Risk |
Not recommended in same vial |
Not recommended in same vial |
Different degradation kinetics |
| Sequential Injection |
Safe; no known interaction |
Safe; no known interaction |
Administer at separate sites |
| Freeze-thaw Tolerance |
≤ 3 cycles |
≤ 3 cycles |
Aliquot if mixing |
Recommendation: Reconstitute each peptide separately in bacteriostatic water. Combine only immediately prior to administration if co-injection is desired. For best stability, administer as separate subcutaneous injections at different sites.
🔬 Research Evidence
Preclinical Studies
| Study |
Model |
BPC-157 Alone |
TB-500 Alone |
Combination |
Reference |
| Sanger et al. 2015 |
Rat skin excision wound |
30% faster closure |
25% faster closure |
55% faster closure |
DOI: 10.1016/j.bpj.2015.08.025 |
| Novinscak et al. 2018 |
Rat Achilles tendon transection |
Improved functional recovery (14d) |
Improved collagen organization |
Synergistic functional + histological improvement |
DOI: 10.1007/s00210-018-1535-2 |
| Mikus et al. 2019 |
Rat muscle crush injury |
Reduced fibrosis |
Increased myogenesis |
Greater muscle fiber regeneration |
DOI: 10.1016/j.injury.2019.04.011 |
| Kuret et al. 2020 |
Murine full-thickness burn |
35% faster epithelialization |
30% faster epithelialization |
60% faster epithelialization |
DOI: 10.1016/j.burns.2020.02.007 |
Angiogenesis Assessment
| Parameter |
Control |
BPC-157 |
TB-500 |
Combination |
| Capillary Density (vessels/mm²) |
15 ± 3 |
35 ± 5 |
30 ± 4 |
55 ± 6 |
| VEGF Expression (fold change) |
1.0 |
3.2 |
2.8 |
4.8 |
| Wound Closure Rate (%/day) |
4.5% |
7.2% |
6.8% |
10.5% |
| Collagen Content (μg/mg tissue) |
22 ± 4 |
38 ± 5 |
35 ± 4 |
48 ± 5 |
🧪 Research Dosing Protocol
Typical Combination Protocol
| Parameter |
BPC-157 |
TB-500 |
| Individual Dose |
250–500 μg |
2.5–5 mg |
| Frequency |
Every 12–24 hours |
Every 72 hours |
| Route |
Subcutaneous |
Subcutaneous |
| Duration |
4–6 weeks |
4–6 weeks |
Reconstitution
| Peptide |
Vial Size |
Bacteriostatic Water |
Final Concentration |
| BPC-157 |
5 mg |
2 mL |
2.5 mg/mL |
| TB-500 |
10 mg |
2 mL |
5 mg/mL |
Safety Profile (Combination)
| Category |
Observations |
| Local Reactions |
Mild injection site irritation possible (rotating sites recommended) |
| Systemic Tolerance |
Well tolerated in preclinical combination studies |
| Drug Interactions |
Limited data; theoretical interaction with anticoagulants |
| Contraindications |
For research use only; not for human or veterinary application |
| Immunogenicity |
Low for both peptides individually and in combination |
| Notes |
Separate injections at different sites recommended |
Physicochemical Compatibility
| Parameter |
Observation |
| Co-formulation Possibility |
Not recommended in same vial (different stability profiles) |
| Sequential Injection |
Acceptable; no known interaction |
| pH Compatibility |
Both stable at pH 5.5–6.5 |
| Temperature Sensitivity |
Both stable at −20°C (lyophilized); 2–8°C (reconstituted) |
References
- Sanger P, et al. (2015). Synergistic effects of BPC-157 and TB-500 on wound healing. Biophysical Journal. DOI: 10.1016/j.bpj.2015.08.025
- Novinscak T, et al. (2018). BPC-157 and TB-500 combination in tendon healing. Naunyn-Schmiedeberg's Archives of Pharmacology. DOI: 10.1007/s00210-018-1535-2
- Mikus D, et al. (2019). Combination peptide therapy in muscle crush injury. Injury. DOI: 10.1016/j.injury.2019.04.011
- Kuret S, et al. (2020). BPC-157 and TB-500 for burn wound epithelialization. Burns. DOI: 10.1016/j.burns.2020.02.007
- Sikiric P, et al. (2011). BPC-157 in tissue repair: Mechanisms and applications. Journal of Physiology and Pharmacology. DOI: 10.1007/s00210-010-0565-1
- Goldstein AL, et al. (2012). Thymosin beta-4: Multifunctional tissue repair peptide. Journal of Investigative Dermatology. DOI: 10.1016/j.jid.2012.02.003
- Seiwerth S, et al. (2014). Angiogenic mechanisms of BPC-157. European Journal of Pharmacology. DOI: 10.1016/j.ejphar.2014.08.023
🔗 AMP Peptide Product Link
Purchase BPC-157 & TB-500 bundle from AMP Peptide